De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trialResearch in context

De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trialResearch in context

Summary: Background: Due to the undesirable cumulative toxicity of multiple drugs, de-escalated neoadjuvant chemotherapy strategies are needed for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Pyrotinib, a small-molecule irreversible pan-HER receptor tyrosine kinase inhibi...

Full description

Saved in:
Bibliographic Details
Main Authors: Hong Pan, Yi Ren, Mengyao Zha, Mingduo Liu, Xiaoan Liu, Hui Xie, Xiaoming Zha, Yi Zhao, Lin Chen, Tiansong Xia, Zhao Liu, Jing Tao, Hua Pan, Yue Sun, Wei Li, Cong Wang, Qiang Ding, Shui Wang, Wenbin Zhou
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:EClinicalMedicine
Subjects:
Breast cancer
HER2
Pyrotinib
Neoadjuvant therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537025003086
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

http://www.sciencedirect.com/science/article/pii/S2589537025003086

Similar Items